SCHEMBL1186909

SCHEMBL1186909

COc1ccc(COc2cccc(C(=O)NNC(C)=O)c2)cc1

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMPD1 P17405 5/20 0.77
▸ RAB9A P51151 5/20 0.60
▸ NPC1 O15118 4/20 0.60
▸ SMN1; SMN2 Q16637 3/20 0.60
▸ ALDH1A1 P00352 2/20 0.60
▸ KDM4E B2RXH2 1/20 0.60
▸ LMNA P02545 1/20 0.60
▸ MEN1 O00255 1/20 0.57
▸ KMT2A Q03164 1/20 0.57
▸ MAOB P27338 5/20 0.56
▸ MAOA P21397 2/20 0.55
▸ MAPT P10636 1/20 0.54
▸ HTT P42858 1/20 0.54
▸ GAA P10253 1/20 0.54
▸ TP53 P04637 1/20 0.53
▸ PKM P14618 1/20 0.53
▸ NFKB1 P19838 1/20 0.53
▸ NFKB2 Q00653 1/20 0.53
▸ RELA Q04206 1/20 0.53
▸ MRGPRX4 Q96LA9 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28587056 0.87 SMPD1 (1.00) SMPD1RAB9ANPC1SMN1; SMN2ALDH1A1
SCHEMBL2254423 0.84 SMPD1 (0.76) SMPD1RAB9ANPC1SMN1; SMN2ALDH1A1
SCHEMBL1186257 0.82 SMN1; SMN2 (0.76) SMPD1RAB9ANPC1SMN1; SMN2MAOB
SCHEMBL30418238 0.81 SMPD1 (0.71) SMPD1RAB9ANPC1SMN1; SMN2ALDH1A1
SCHEMBL7438620 0.81 SMPD1 (0.71) SMPD1RAB9ANPC1SMN1; SMN2ALDH1A1
SCHEMBL3161746 0.79 SMPD1 (0.65) SMPD1RAB9ANPC1SMN1; SMN2ALDH1A1
SCHEMBL12871351 0.79 NPC1 (0.90) RAB9ANPC1SMN1; SMN2ALDH1A1KDM4E
SCHEMBL7048265 0.79 SMPD1 (0.60) SMPD1RAB9ANPC1SMN1; SMN2ALDH1A1
SCHEMBL8983027 0.78 SMPD1 (0.67) SMPD1RAB9ANPC1SMN1; SMN2ALDH1A1
SCHEMBL15825021 0.78 SIRT2 (0.68) SMPD1RAB9ANPC1SMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2297129-B1 SUBSTITUTED CYCLOPROPYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT MERCK SHARP & DOHME (US) 2013-07-24 — — EP disclosed
US-8343990-B2 Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment MERCK SHARP & DOHME CORP. (US) 2013-01-01 — — US disclosed
US-20110028501-A1 SUBSTITUTED CYCLOPROPYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT MERCK SHARP & DOHME LLC 2011-02-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110028501-A1 SUBSTITUTED CYCLOPROPYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT GPR119, GPR27, GPR139 SMPD1 874/4885RAB9A 1180/4885NPC1 531/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback